Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
News for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) is closely tied to developments at LifeMD, Inc., the issuer of this preferred security. LifeMD regularly publishes updates about its virtual primary care and pharmacy operations, financing activities, and corporate governance, all of which can be relevant to investors following LFMDP.
Company announcements describe LifeMD as a provider of virtual primary care services and pharmacy solutions, with telemedicine, laboratory access, and pharmacy services supporting treatment across more than 200 conditions. News items highlight growth in telehealth revenue, expansion into areas such as weight management, women’s health, mental and behavioral health, and cardiometabolic care initiatives, and the evolution of its virtual care platform.
Investors tracking LFMDP can expect news related to LifeMD’s clinical programs, including collaborations with pharmaceutical manufacturers. Recent releases discuss expanded collaboration with Novo Nordisk, access to Wegovy and Ozempic within LifeMD’s weight management program, and the addition of the Wegovy pill to its virtual obesity care offering. Other updates cover developments in women’s health programs, including the appointment of clinical advisors, and the scaling of men’s health and RexMD-branded services.
Corporate and financial news is also significant for LFMDP followers. LifeMD has issued press releases on quarterly financial results, changes in independent registered public accounting firms, the divestiture of its majority interest in WorkSimpli Software LLC to focus on virtual care and pharmacy, and the establishment of a revolving credit facility. The company has additionally announced quarterly cash dividends on the 8.875% Series A Cumulative Perpetual Preferred Stock.
By reviewing the LFMDP news feed, readers can monitor how LifeMD’s virtual care strategy, partnerships, financial decisions, and governance updates may influence the context in which this preferred stock operates. Regular news provides a consolidated view of operational milestones and capital structure developments that matter to preferred and common equity holders alike.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend payment of $0.5546875 per share will be distributed on April 15, 2025, to shareholders of record as of April 4, 2025.
LifeMD (NASDAQ: LFMD) reported strong Q4 2024 financial results with consolidated revenues increasing 43% year-over-year to $64.3 million, driven by a 60% growth in telehealth revenue. The company achieved record quarterly adjusted EBITDA of $9.0 million, up 78% year-over-year.
Key highlights include telehealth adjusted EBITDA increasing 396% to $5.9 million, telehealth active subscribers growing 27% to 275,000, and WorkSimpli subscribers rising 3% to 164,000. The company ended 2024 with over $35 million in cash and improved full-year cash flow from operations by 99% to $17.5 million.
For 2025, LifeMD provided guidance of $265-275 million in consolidated revenue and $30-32 million in consolidated adjusted EBITDA. The company plans to launch Medicare services on April 1 and is preparing to introduce virtual-first behavioral health and women's health specialty offerings later in the year.
LifeMD (Nasdaq: LFMD) announced integration with LillyDirect's pharmacy provider Gifthealth to offer streamlined access to Zepbound® (tirzepatide), Lilly's FDA-approved prescription obesity treatment. The integration enables eligible patients to access single-dose vials at reduced self-pay prices with direct shipment.
Zepbound is the first dual GLP-1/GIP obesity medication approved by FDA. The integration complements LifeMD's insurance-sponsored pharmacy programs, where approval rates for branded GLP-1 therapies are increasing. The company's weight management program has reached approximately 75,000 active patient subscribers as of February 2025.
Through LillyDirect's self-pay pharmacy channel, Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg dose vials. Lilly has reduced prices for 2.5 mg and 5 mg vials and launched new 7.5 mg and 10 mg vial options.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its upcoming participation in the KeyBanc Capital Markets Healthcare Forum. The event will be held virtually from March 18-19, 2025.
The company's management team is scheduled to engage in a fireside chat on Tuesday, March 18th at 11:15 a.m. Eastern time. Additionally, they will conduct one-on-one meetings throughout the duration of the conference.
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, has announced it will report its financial results for the fourth quarter and full year of 2024 on March 10, 2025.
The company will release its three and 12-month financial results ended December 31, 2024, after the close of U.S. financial markets on the scheduled date. Following the release, LifeMD will host a conference call beginning at 4:30 p.m. Eastern time to discuss the results.
LifeMD (NASDAQ: LFMD) announced its expansion into the behavioral health market, adding teletherapy, psychiatry, and medication management services for mental health conditions. The company appointed Julian Cohen as Senior Vice President of Behavioral Health & Clinical Operations to lead this initiative.
Cohen brings over 30 years of healthcare industry experience, including executive roles at UpLift, Hims, Teladoc Behavioral Health, and as co-founder/CEO of Breakthrough Behavioral. The expansion aims to address the significant mental health treatment gap, as only 50.6% of the 59.3 million U.S. adults with mental illness received treatment in 2022.
LifeMD plans to improve accessibility through expanded insurance coverage across commercial and government payers. The company particularly notes the high prevalence of mental health conditions among young adults (36.2%) and the correlation between obesity and psychiatric illness (20-60% of obese individuals).
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference is scheduled for February 11-12, 2025, and will take place at the Cliff Lodge in Snowbird, Utah. The company's management team will be conducting one-on-one meetings throughout the duration of the conference.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has announced a quarterly dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend payment of $0.5546875 per share will be distributed on January 15, 2025, to shareholders of record as of January 3, 2025.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in the Mizuho Health Care Conference: Medical Device, Services, Technology and Distribution. The event will take place on December 11, 2024 at the Sofitel New York.
The company's management team will be available for one-on-one meetings with investors throughout the conference day. Institutional investors who wish to meet with LifeMD management at the conference should coordinate through their Mizuho Securities representative.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in three major investor conferences this November. The company will attend the Craig-Hallum 15th Annual Alpha Select Conference on November 19 at the Sheraton NY Times Square Hotel, the Stephens NASH24 Conference on November 20 at the Grand Hyatt Nashville, and the BTIG Digital Health Forum on November 25. At BTIG, management will participate in a panel discussion titled 'Primary Care is the Solution' at 10:00 a.m. Eastern time. The management team will be available for one-on-one meetings with investors at all three events.
FAQ
What is the current stock price of Lifemd (LFMDP)?
